Shots:

• The companies collaborate to explore the combination of Seven and Eight’s BDB001 and Merck’s Keytruda (pembrolizumab) for treating patients with advanced solid tumors
• As per the agreement- Seven and Eight BioPharmaceuticals will conduct the clinical study assessing the combination regimen to address the unmet medical needs of patients with advanced and difficult-to-treat tumor types
• BDB001 is an immune modulator targeting TLR 7 & 8 while Keytruda is an anti-PD-1 therapy- act by blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells

Click here to­ read full press release/ article 

Ref: Businesswire | Image: Merck